Drug
Voncento
Voncento: highest development phase Post-Market, developed by CSL. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- CSL
Trials
| Drug | Phase | Indication |
|---|---|---|
| Voncento NCT02552576 | Post-Market | Von Willebrand Disease |
Latest
No recent events.
Follow Voncento on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.